Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

Definium Therapeutics reported its third-quarter 2026 financial results and provided an update on its psychiatric and neurological drug pipeline. The company also announced positive initial Phase 2a trial data for DT402 in adults with autism spectrum disorder. The article does not specify financial figures or any stock-price impact.